Eli Lilly to Manufacture Experimental Weight-Loss Pill at New $6.5 Billion Texas Facility
U.S. pharmaceutical giant Eli Lilly has announced plans to produce its next-generation experimental weight-loss pill, orforglipron, at a newly proposed $6.5 billion manufacturing facility in Texas. The investment marks one of the company’s largest single-site expansions and reflects growing demand for obesity treatments worldwide. Orforglipron, a once-daily oral GLP-1 receptor agonist, is currently undergoing clinical […]
Continue Reading